ACADIA Pharmaceuticals Inc (ACAD) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Adjusted Total Revenues (Q4 2025): $298 million, up 16% year-over-year. Annual Adjusted Revenues (2025): $1.08 billion, representing 14% growth from the prior year. Adjusted New Placid Net Sales (Q4 2025): $189 million, up 17% year-over-year. Annual Adjusted New Placid Net Sales (2025): $692 million, up 15% year-over-year. Debut Net Product Sales (Q4 2025): $110 million, up 13% year-over-year. Annual Debut Net Product Sales (2025): $391 million, up 12% year-over-year. Cash Balance (End of 2025): $820 million. SG&A Expenses (Q4 2025): $156 million, up from $130 million in Q4 2024. R&D Expenses (Q4 2025): $85 million, down from $101 million in Q4 2024. 2026 Revenue Guidance: $1.22 to $1.28 billion. 2026 New Placid Net Sales Guidance: $760 to $790 million. 2026 Debut Net Sales Guidance: $460 to $490 million. Warning! GuruFocus has detected 4 Warning Sign with ACAD. Is ACAD fairly valued? Test your thesis with our free
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- ACADIA Pharmaceuticals (ACAD) had its price target raised by TD Cowen from $35.00 to $37.00. They now have a "buy" rating on the stock.MarketBeat
- ACADIA Pharmaceuticals (ACAD) had its price target lowered by Royal Bank Of Canada from $31.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- ACADIA Pharmaceuticals (ACAD) had its price target raised by Citizens Jmp from $34.00 to $35.00. They now have a "market outperform" rating on the stock.MarketBeat
- ACADIA Pharmaceuticals (ACAD) had its price target lowered by Stifel Nicolaus from $25.00 to $24.00. They now have a "hold" rating on the stock.MarketBeat
- ACADIA (ACAD) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
ACAD
Earnings
- 2/25/26 - Beat
ACAD
Sec Filings
- 2/26/26 - Form SCHEDULE
- 2/26/26 - Form 10-K
- 2/25/26 - Form 8-K
- ACAD's page on the SEC website